Literature DB >> 337890

Factors governing the emergence of resistance to nalidixic acid in treatment of urinary tract infection.

D Greenwood, F O'Grady.   

Abstract

Cultures of Escherichia coli were exposed to nalidixic acid in an in vitro model in which the conditions of drug-organism interaction resembled those of bacterial cystitis treatment. Results obtained in this way suggested that emergence of bacterial resistance should not be a major problem in treatment of uncomplicated urinary infection; such cases might indeed respond to a less intensive course of treatment than is usual. More prolonged, high-dosage therapy with nalidixic acid may be required for patients with more complicated infections if the risk of failure from the emergence of bacterial resistance is to be minimized.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 337890      PMCID: PMC430003          DOI: 10.1128/AAC.12.6.678

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  NALIDIXIC ACID IN URINARY INFECTIONS.

Authors:  J F WARD-MCQUAID; D JICHLINSKI; R MACIS
Journal:  Br Med J       Date:  1963-11-23

2.  NALIDIXIC ACID IN INFECTIONS OF URINARY TRACT. LABORATORY AND CLINICAL INVESTIGATIONS.

Authors:  A M BARLOW
Journal:  Br Med J       Date:  1963-11-23

3.  Factors influencing the response of Escherichia coli to antibiotics in conditions prevailing in the infected urinary bladder.

Authors:  D Greenwood; F O'Grady
Journal:  Br J Exp Pathol       Date:  1976-06

4.  Resistance to nalidixic acid. A misconception due to underdosage.

Authors:  T A Stamey; J Bragonje
Journal:  JAMA       Date:  1976-10-18       Impact factor: 56.272

5.  Treatment of "bacterial cystitis" in fully automatic machanical models simulating conditions of bacterial growth in the urinary bladder.

Authors:  F O'Grady; I P Mackintosh; D Greenwood; B W Watson
Journal:  Br J Exp Pathol       Date:  1973-06

6.  Comparison of the responses of Escherichia coli and proteus mirabilis to seven beta-lactam antibodies.

Authors:  D Greenwood; F O'Grady
Journal:  J Infect Dis       Date:  1973-08       Impact factor: 5.226

7.  A twelve channel bacterial growth monitoring system.

Authors:  I P Mackintosh; F O'Grady; D Greenwood; B W Watson; T C Crichton; R Piper; A Ferrer
Journal:  Biomed Eng       Date:  1973-12

8.  Relation between residual urine volume and response to treatment of urinary infection.

Authors:  D G Shand; C C Nimmon; F O'Grady; W R Cattell
Journal:  Lancet       Date:  1970-06-20       Impact factor: 79.321

9.  Observations on bacterial sensitivities to nalidixic acid and critical comments on the 6-centre survey.

Authors:  W Brumfitt; R Pursell
Journal:  Postgrad Med J       Date:  1971-09       Impact factor: 2.401

10.  Nalidixic acid and oxolinic acid in the treatment of chronic bacteriuria.

Authors:  E Atlas; H Clark; F Silverblatt; M Turck
Journal:  Ann Intern Med       Date:  1969-04       Impact factor: 25.391

View more
  5 in total

1.  Studies on the emergence of resistance to lomefloxacin in vitro.

Authors:  M Kanematsu; D Greenwood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

2.  Comparison of norfloxacin versus nalidixic acid in therapy of acute urinary tract infections.

Authors:  L K Selin; G K Harding; M J Thomson; J K Kennedy; B A Urias; A R Ronald
Journal:  Can J Infect Dis       Date:  1990

3.  Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis.

Authors:  D Greenwood; S Baxter; A Cowlishaw; A Eley; G J Slater
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

4.  Activity of flumequine against Escherichia coli: in vitro comparison with nalidixic and oxolinic acids.

Authors:  D Greenwood
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

Review 5.  Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections.

Authors:  T S Sisca; R C Heel; J A Romankiewicz
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.